Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
NCT05711719Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Jun 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic syndrome and Coronary Microvascular Dysfunction (CMD) comparing Vericiguat with Placebo (2 arms). Primary endpoints: Absolute Change in Coronary Cross-sectional Area at 6 weeks and Relative Change in Coronary Cross-sectional Area at 6 weeks. Started Jun 2023; status: completed.
02
Drugs
vericiguat
03
Conditions
metabolic syndromeCoronary Microvascular Dysfunction (CMD)
Beyond the preview
Go deeper on NCT05711719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05711719.